Grail Cancer Blood Test Fails Key NHS Trial, Shares Plummet

Grail Inc. Shares plummeted on Thursday after the diagnostics firm announced that its highly anticipated multi-cancer early detection test, Galleri, failed to meet the primary endpoint in a large-scale clinical trial conducted with the United Kingdom’s National Health Service (NHS). The stock closed down nearly 30% in after-hours trading, despite reporting a narrower-than-expected quarterly loss.

The trial, known as NHS-Galleri, aimed to demonstrate a statistically significant reduction in combined Stage III and IV cancer diagnoses through the implementation of Galleri testing. While detailed results are currently behind a paywall at STAT News, the company confirmed the primary endpoint was not met. This setback casts a shadow over the future of the test, which has been touted as a potential game-changer in cancer detection.

Grail’s Galleri test analyzes a blood sample for early signs of multiple cancer types, aiming to detect the disease before symptoms appear. The list price for the test is currently $1,000. Despite the trial’s disappointing outcome, the company reported selling 185,000 tests in the 2025 fiscal year, generating $136.8 million in revenue. U.S. Revenue for Galleri grew 26% year-over-year to $136.8 million, driven by partnerships with digital health platforms like Hims & Hers.

The financial results presented a mixed picture. Grail reported a fourth-quarter net loss of $99.2 million, or $2.44 per share, which was better than the analyst consensus estimate of a $4.01 loss. This suggests that despite the clinical trial setback, the company is managing its expenses effectively. However, investors clearly prioritized the clinical data over the financial beat, sending the stock price sharply lower.

The failure of the NHS-Galleri trial is particularly significant because of the scale of the study and the prominence of the NHS. The NHS is the publicly funded healthcare system of the United Kingdom and a successful trial within the NHS would have provided a strong validation of the test’s effectiveness and paved the way for wider adoption. The NHS-Galleri trial involved a large patient population and real-world clinical settings, making its results highly influential.

Despite the setback, Grail’s Chief Executive Officer Bob Ragusa attempted to frame the results positively, emphasizing that adding the Galleri test to standard care resulted in a four-fold improvement in overall cancer detection rates compared to standard screening alone. He stated that the trial provides “the strongest evidence to date that multi-cancer early detection can shift the stage at which cancers are detected at a population level.” However, this claim focuses on an improvement in overall detection rates, rather than the primary endpoint of reducing Stage III and IV diagnoses.

The company maintains a strong financial position, ending the year with $904.4 million in cash, cash equivalents, and short-term marketable securities. Management believes this provides a financial runway extending into 2030, allowing them to pursue broader commercial access for Galleri. However, the lack of a positive signal from the NHS-Galleri trial will likely complicate those efforts.

The implications of this trial failure extend beyond Grail itself. The company has been a leading proponent of multi-cancer early detection, and its technology has attracted significant investment and attention. The disappointing results may raise questions about the viability of this approach to cancer screening, potentially impacting other companies working in the same space.

Johnson Fistel is currently investigating potential claims against Grail, Inc., citing the drop in share price and the disappointing trial results. This suggests that shareholders may be considering legal action against the company, alleging that they were misled about the prospects for Galleri.

The future of Galleri remains uncertain. While the company continues to pursue commercialization in the U.S. And other markets, the lack of a positive signal from the NHS-Galleri trial will likely make it more difficult to gain widespread acceptance. The company will need to demonstrate compelling evidence of the test’s clinical and economic value to convince healthcare providers and payers to adopt it. The focus will likely shift to demonstrating the cost-effectiveness of earlier detection, even if it doesn’t translate directly into a reduction in late-stage diagnoses.

The broader implications for the field of multi-cancer early detection are also significant. While Grail’s technology has been at the forefront of this emerging area, the NHS-Galleri trial failure underscores the challenges of developing and validating these types of tests. Further research and development will be needed to improve the accuracy, specificity, and clinical utility of multi-cancer early detection technologies.